Concepedia
Statistics
Publications
7
Citations
337
H-Index
Active since
2013
Affiliations
Pfizer (United States)(Current)
Utah State University
Irina Yurgelonis is an author at Pfizer (United States) specializing in virology, life sciences, and infectious diseases.
Publications per year
2013–2024
A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile
Robert G. K. Donald, Mike Flint, Narender K. Kalyan et al. · Microbiology · 2013 · 93 citations · Full text
Life Sciences, Biotechnology, Immunology +17
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner et al. · Journal of Medicinal Chemistry · 2024 · 73 citations · Full text
Medicine, Infectious Diseases, Pharmacology +15
Discovery of SARS-CoV-2 papain-like protease (PL <sup>pro</sup> ) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen et al. · Science Advances · 2024 · 49 citations · Full text
Life Sciences, Infectious Diseases, Pharmacology +17
In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance
Yuao Zhu, Irina Yurgelonis, Stephen Noell et al. · Science Advances · 2024 · 45 citations · Full text
Life Sciences, Infectious Diseases, Microbiology +16
Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern
Irina Yurgelonis, Patricia McMonagle, Hussin A. Rothan et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022 · 34 citations · Full text
Life Sciences, Infectious Diseases, Pharmacotherapy +17
1–5 of 7